The pharmacokinetics and pharmacodynamics of Procysteine in amyotrophic lateral sclerosis
- 1 April 1999
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 52 (7), 1492
- https://doi.org/10.1212/wnl.52.7.1492
Abstract
Article abstract In 13 subjects with ALS, we studied the safety and pharmacokinetic properties of Procysteine, a cysteine prodrug that increases levels of intracellular glutathione. We found that oral administration of Procysteine was safe. Procysteine enters CSF after both IV and oral dosing and accumulates to significant levels in CSF. We also observed that CSF levels of glutathione fall dramatically with aging.Keywords
This publication has 6 references indexed in Scilit:
- Age‐Related Changes in Lipid Peroxidation and Antioxidant Defense in Fischer 344 RatsaAnnals of the New York Academy of Sciences, 1996
- Randomized, Double-Blind, Controlled Trial of Acetylcysteine in Amyotrophic Lateral SclerosisArchives of Neurology, 1995
- Marked increase of cysteine levels in many regions of the brain after administration of 2‐oxothiazolidine‐4‐carboxylateThe FASEB Journal, 1989
- Administration of l-2-oxothiazolidine-4-carboxylate increases glutathione levels in rat brainBrain Research, 1989
- Spinal cord TRH deficiency is associated with incomplete recovery of denervated muscle in the ratNeurology, 1988
- Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis.Proceedings of the National Academy of Sciences, 1982